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Abstract
Background: The use and effectiveness of hematopoietic stem cell transplantation (HSCT) are limited by lethal
complications, i.e., acute and chronic graft-versus-host disease (aGVHD and cGVHD, respectively), in which immune
cells from the donor attack healthy recipient tissues. GVHD presents both prophylactic and therapeutic challenges,
and overall survival is poor. Mesenchymal stem cells (MSCs) show considerable promise in the treatment of GVHD
because of their potential immunomodulatory activity. Multiple studies have been performed to explore the
possible benefit of MSCs in GVHD, but the results of these studies are sometimes conflicting. Therefore, we
performed a systematic review and meta-analysis to estimate the effect of MSC infusion on GVHD treatment and
prevention.
Methods: We systematically searched the MEDLINE (PubMed), Cochrane Library, EMBASE, ClinicalTrials.gov, and
SinoMed CBM databases to identify studies published before February 2018 involving patients with hematologic
malignancies undergoing HSCT and receiving MSC-based or conventional therapy. We included studies if they
reported on the outcomes of interest.
Results: Ultimately, 10 studies were selected from among 413 candidates. According to our meta-analyses,
compared with conventional treatment, MSC therapy demonstrated substantial improvements in terms of complete
response (CR) and overall survival for cGVHD. However, MSC therapy did not show substantial improvements in
terms of engraftment, the incidence of aGVHD, relapse, death, death due to relapse, or death due to infection.
Subgroup analyses showed that MSCs derived from the umbilical cord (U-MSCs) and MSC infusion after HSCT
substantially improved engraftment and cGVHD incidence, whereas MSCs derived from bone marrow (B-MSCs) and
MSC infusion before HSCT shows no improvement. In addition, B-MSCs and MSC infusion before HSCT tend to
prolong engraftment time, as well as increase the rates of relapse and death.
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Conclusions: MSC infusion can reduce cGVHD but not aGVHD incidence and showed a positive effect in patients
who already had aGVHD. For GVHD prevention, the use of U-MSCs and MSC infusion after HSCT were optimal for
reducing cGVHD incidence and promoting engraftment, and might help decrease the incidence rate of relapse and
death. However, B-MSCs and MSC infusion before HSCT may be harmful to patients and thus require serious
consideration. A lack of robust evidence, owing to the small number of studies and small sample sizes, indicates a
need for further high-quality clinical trials including large numbers of patients to validate our findings.
Keywords: Mesenchymal stem cells, Stem cell transplantation, Graft-versus-host disease, Meta-analysis
Background
Hematopoietic stem cell transplantation (HSCT) is an
intensive therapy used to treat hematologic malignant
disorders and genetic diseases. Modern approaches to
human leukocyte antigen-haploidentical blood or mar-
row transplantation [1], and improvements of trans-
plantation outcomes, have led to greater use of HSCTs.
The number of HSCT procedures continues to increase,
with more than 60,000 performed annually according to
the Center for International Blood and Marrow Trans-
plant Research [2]. However, its major lethal complica-
tion, graft-versus-host disease (GVHD), which may
manifest as acute GVHD (aGVHD) or chronic GVHD
(cGVHD), limits the effectiveness of HSCT [3].
GVHD is an immunological disorder in which im-
mune cells from the donor attack healthy recipient tis-
sues, including the gastrointestinal tract, liver, skin, and
lungs. GVHD occurs in more than 50% of patients
undergoing HSCT [4]. According to the extent of in-
volvement of the affected organs, aGVHD is categorized
into four types: I (mild), II (moderate), III (severe), and
IV (very severe), while cGVHD is subdivided into limited
cGVHD and extensive cGVHD. Given the current trend,
the number of transplants from unrelated donors is
expected to double within the next 5 years and will sub-
stantially increase the number of patients with GVHD.
The threat posed by GVHD to patient survival is also
gradually increasing.
GVHD presents both prophylactic and therapeutic chal-
lenges. Prophylactically, pharmacological manipulation of
T cells after transplantation is the most commonly used
preventive strategy. Administration of antibodies against
T cells in vivo for GVHD prevention has been tested ex-
tensively using antithymocyte globulin (ATG) and antil-
ymphocyte globulin (ALG) preparations. Unfortunately,
neither drug is optimal for enhancing long-term survival,
despite reducing the frequency of GVHD. Therapeutically,
a steroid regimen, given their potent antilymphocyte and
anti-inflammatory effects, remains the gold standard for
treatment of GVHD [5]. However, less than half of pa-
tients with GVHD who underwent treatment with steroids
achieved complete remission; on the contrary, more pa-
tients became steroid-refractory and showed very poor
overall survival [6–8]. Despite important advances in the
field of HSCT over the past few years, there has been little
improvement in the morbidity or mortality of GVHD [9].
Patients with severe GVHD have a dismal estimated long-
term survival rates, of 25% (5 years) for grade III and 5%
for grade IV [10]. Allogeneic transplantation is becoming
an increasingly attractive therapeutic option, thus acceler-
ating the search for novel approaches to GVHD.
A cell-based therapeutic approach, using mesenchymal
stem cells (MSCs), has recently shown considerable
promise because of their expected immunomodulatory
effects [11, 12]. MSCs are plate-adhering, fibroblast-like
cells known for their self-renewal capacity and ability to
differentiate into multiple mesenchymal cell lineages
[13]. In addition to their differentiation potential, MSCs
are immunosuppressive. Bartholomew et al. first demon-
strated that MSC administration in vivo could prolong
skin graft survival [14]. Many subsequent in vitro and in
vivo studies have confirmed the immunomodulatory ac-
tivity of MSCs, by showing that they can inhibit the pro-
liferation and functions of T cells, B cells, dendritic cells,
and natural killer cells [15–18]. Studies have also re-
ported that MSCs play an active role in promoting facili-
tation of HSC engraftment following transplantation,
because they are part of the HSC niche, wherein they
support hematopoiesis [19, 20]. Owing to the growing
understanding of MSCs, they have become an exciting
tool for treating prophylaxis and GVHD in the HSCT
setting and have been approved for use in clinical trials
as immunomodulators [21].
Since Le Blanc et al. first reported complete remission
of steroid-resistant aGVHD in a child receiving MSC
infusions [22], multiple studies have been performed to
explore the possible benefit of MSCs in GVHD. How-
ever, results are conflicting as to whether MSC infusion
during HSCT is effective in managing GVHD [23].
Canada, New Zealand, and some EU countries have ap-
proved Prochymal®, the first MSC drug released to the
market, for the treatment of children with steroid-
refractory GVHD, while other countries including the
USA and China have not. The field of MSC therapy is
faced with a paradox regarding the clinical utility of
MSCs for GVHD, with opposite clinical outcomes in the
Zhao et al. Stem Cell Research & Therapy          (2019) 10:182 Page 2 of 13
USA and Europe [23]. A previous meta-analysis [2] of
uncontrolled studies with single-arm design was published
in 2016 and showed that MSC treatment had a positive
effect on 6-month survival in patients with aGVHD. How-
ever, no pooled analysis based on controlled trials has con-
firmed this report. The efficacy of MSC infusion for
GVHD prevention is also controversial, with research vari-
ously showing both a significant benefit [24] and no bene-
fit [25]. As evidence accumulates, it is essential to explore
whether use of MSCs is favorable for GVHD, which repre-
sents the first area of clinical application of MSCs. There-
fore, we performed a systematic review and meta-analysis
of controlled trials to determine the effect of MSC infu-
sion for both GVHD treatment and prevention.
Methods
Search strategy and selection criteria
We searched the Medline (PubMed) [26], Cochrane
Library [27], EMBASE [28], ClinicalTrials.gov [29], and
SinoMed CBM [30] databases up to February 2018 to
identify relevant studies using a combined free text and
MeSH heading search strategy (see Additional file 1),
with no language or time restrictions. The retrieval strat-
egy was based on the patient–intervention–comparison–
outcome (PICO) principle and was enhanced by adding
keywords related to GVHD (“graft versus host disease”,
“graft vs. host disease” and “GVHD”) and mesenchymal
stem cells (“mesenchymal stem cell*”, “mesenchymal
stromal cell*”, and “multipotent stromal cell*”). We also
checked the reference lists of the retrieved studies for
additional relevant studies. The inclusion criteria were
(1) randomized controlled trials (RCTs) for GVHD pre-
vention, (2) controlled trials for GVHD treatment, (3)
inclusion of patients who underwent HSCT, (4) use of
MSC, and (5) availability of treatment outcome parame-
ters [complete response (CR) and overall survival] or
prevention-related data [engraftment, aGVHD, cGVHD,
relapse, death, death due to relapse, and death due to in-
fection]. Studies were excluded if they were animal-
based, review articles, or case reports. When duplicate
reports from the same study were identified, the one in-
cluding more information or a longer follow-up period
was selected.
Data extraction and statistical analysis
For each study, data were extracted by one investigator
and reviewed by a second investigator to ensure accur-
acy. Information on the following was extracted: patients
(number, age, sex, disease information), MSCs (number,
source, dose, number of infusions, and infusion timing),
outcome parameters during the follow-up period, and
study information (author, publication year, country,
study design, and follow-up period).
A meta-analysis was conducted to evaluate whether the
efficacy of MSC-based therapy was greater than that of
conventional therapy in terms of GVHD prevention and
treatment. Outcome parameters were evaluated by calculat-
ing the risk ratio (RR) or standardized mean difference
(SMD) with 95% confidence intervals (CIs). The percentage
of variability across studies attributable to heterogeneity
beyond chance was assessed using the chi-square-based Q
test (P < 0.1 was considered indicative of significance) and
I2 statistic (I2 > 50% indicated high heterogeneity). A forest
plot was used to visualize the RR and 95% CI for each
study. A random-effects model was used because it pro-
vides a more conservative estimate of the presence of het-
erogeneity. A sensitivity analysis, with omission of one
study at a time, was conducted to assess heterogeneity.
Where sufficient studies were available, publication bias
was assessed by the Egger test and visualized using Begg
funnel plots [31]. Subgroup meta-analyses were con-
ducted based on MSC source [bone marrow (B-MSCs)
or umbilical cord (U-MSCs)] and MSC infusion timing
(before HSCT or after HSCT), to identify factors re-
lated to the therapeutic efficacy of MSCs. All analyses
were conducted using R software (version 3.4.0; R
Development Core Team, Vienna, Austria).
Results
Study selection
As shown in Fig. 1, a total of 413 potentially eligible
articles were identified by searching the five databases
and the reference lists of the retrieved studies. Of
these, 53 duplicate articles were excluded. After read-
ing the titles, a further 152 articles were excluded (52
irrelevant papers, 36 animal experiments, 46 reviews
and 18 case reports). After reading the abstracts, 181
additional articles were excluded (31 irrelevant papers,
12 animal experiments, 59 reviews, 71 uncontrolled
trials, and 8 case reports). Among the remaining 27
articles, 23 concerned prevention and 4 concerned
treatment. After assessing the complete texts, 16 of
the 23 prevention-related articles were excluded be-
cause they were non-randomized controlled trials
(nRCTs). The four treatment-related articles included
two RCTs and two nRCTs. The two RCTs were meet-
ing abstracts and one [32] of them was excluded
because outcome parameters could not be extracted
(i.e., survival rate was not reported, and the exact
number of cases showing a CR was not available). The
remaining three articles were included regardless of
whether or not they were RCTs, as controlled trials
related to treatment were limited. Thus, seven RCTs
[9, 24, 25, 33–36] on prevention and three on treat-
ment (two nRCTs [37, 38] and one RCT [39]) were
finally analyzed.
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Characteristics of the included studies
The characteristics of all 10 studies are presented in
Tables 1 and 2. The studies were published between
2008 and 2017 and were conducted in China, Russia,
Italy, and Sweden. The sample size ranged from 20 to
124 participants with malignant hematological diseases.
Seven studies for prevention included a total of 402 pa-
tients and three studies for treatment included a total of
103 patients. All patients were treated with HSCT with
or without an MSC infusion. The MSCs were B-MSCs
or U-MSCs. The dose of infused MSCs ranged from
3.4 × 105 to 7.2 × 106 per kilogram. Infusions were only
administered once for prevention, except in one study
[9] wherein patients received multiple infusions. Infu-
sions were administered multiple times for treatment,
except for one [38] that did not report these data. MSCs
were infused before [24, 36] or after [9, 25, 33–35] HSCT
to prevent GVHD. For treatment, the median duration of
aGVHD before MSC infusion ranged from 8 to 20 days.
The follow-up period ranged from 12 to 70months for
prevention and 139 to 1312 days for treatment.
Meta-analysis for treatment
Among three articles, a total of 103 patients were suffer-
ing from aGVHD, 57 of whom underwent conventional
treatment (control group); the remaining 46 patients
received additional MSC infusions (MSC group).
Complete response
Two studies reported the number of patients with
aGVHD who showed a CR in both MSC and control
groups. Compared with the control group, patients in
Fig. 1 Flowchart of study selection
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the MSC group had a significantly higher rate of CR
(RR = 2.28; 95% CI: 1.24, 4.18; I2 = 0%, P = 0.97; Fig. 2).
Overall survival
Three studies reported the number of patients with
aGVHD who were alive during the follow-up in both the
MSC and control groups. Compared with the control
group, patients in the MSC group had a significantly
higher rate of survival (RR = 1.93; 95% CI 1.12, 3.32; I2 =
41%, P = 0.18; Fig. 2).
Meta-analysis for prevention
Among seven RCTs on GVHD prevention, a total of 402
patients with hematologic malignancies underwent
HSCT, of whom 205 were undergoing conventional
GVHD prevention (control group); the remaining 197
patients received additional MSC infusions (MSC group)
.
Engraftment
Three studies reported the mean time to neutrophil en-
graftment (absolute neutrophil count > 0.5 × 109/L) in
both the MSC and control groups. Compared with the
control group, patients in the MSC group had a shorter
time to neutrophil engraftment, but the difference was not
statistically significant (SMD= − 1.20; 95% CI − 2.57, 0.17;
I2 = 88%, P < 0.01). Significant heterogeneity existed and
sensitivity analyses showed that the study of Ning [24] had
the largest effect on the heterogeneity. Excluding this study
decreased the heterogeneity to a non-significant level
(SMD= − 1.89; 95% CI − 2.42, − 1.37; I2 = 0%, P = 0.91).
The heterogeneity was likely related to the different sources
used of MSCs. According to a subgroup analysis based on
the source of MSCs (B-MSCs or U-MSCs), the U-MSC
subgroup (SMD= − 1.89; 95% CI − 2.42, − 1.37) showed a
significantly shorter time to neutrophil engraftment in the
MSC group compared with the control group, whereas the
B-MSC subgroup (SMD= 0.13; 95% CI − 0.67, 0.93)
showed a longer (but not statistically significant) time to
neutrophil engraftment. According to a subgroup analysis
based on MSC infusion time (before or after HSCT), the
after subgroup (SMD= − 1.91; 95% CI − 2.51, − 1.31)
showed a significantly shorter latency to neutrophil engraft-
ment compared with the control group, whereas the before
subgroup (SMD= − 0.82; 95% CI − 2.74, 1.10) showed a
shorter but not statistically significant time to neutrophil
engraftment. These results are shown in Fig. 3.
Acute GVHD
Five studies reported the number of patients who devel-
oped aGVHD within 100 days after HSCT in both the
MSC and control groups. Compared with the control
group, patients in the MSC group had a lower risk of
aGVHD, but the difference was not statistically signifi-
cant (RR = 0.59; 95% CI 0.34, 1.03; I2 = 39%, P = 0.16).
According to a subgroup analysis based on the source of
MSC, both the B-MSC (RR = 0.46; 95% CI 0.19, 1.11)
and U-MSC (RR = 0.75; 95% CI 0.34, 1.67) subgroups
showed a non-significantly lower risk of aGVHD com-
pared with the control group. A subgroup analysis based
on MSC infusion time also showed that both the before
(RR = 0.47; 95% CI 0.11, 2.02) and after (RR = 0.57; 95%
CI 0.25, 1.30) subgroups had a non-significantly lower
risk of aGVHD compared with the control group. These
results are shown in Fig. 3.
Chronic GVHD
Six studies reported the number of patients who de-
veloped cGVHD in both the MSC and control groups.
Compared with the control group, patients in the
(A)
(B)
Fig. 2 Forest plot of graft-versus-host disease (GVHD) treatment. Compared with the control group, a the rate of complete response and b the
rate of overall survival were significantly higher in the mesenchymal stem cell (MSC) group. Subgroup analyses could not be conducted because
of an insufficient number of studies
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MSC group had a significantly lower risk of cGVHD
(RR = 0.61; 95% CI 0.45, 0.83; I2 = 0%, P = 0.59). Ac-
cording to a subgroup analysis based on the source of
MSC, only the U-MSC subgroup (RR = 0.49; 95% CI
0.28, 0.85) showed a significantly lower risk of
cGVHD compared with the control group; the B-
MSC subgroup (RR = 0.70; 95% CI 0.47, 1.07) showed
a non-significantly lower risk of cGVHD. According
to a subgroup analysis based on MSC infusion time,
only the after subgroup (RR = 0.63; 95% CI 0.46, 0.86)
showed a significantly lower risk of cGVHD com-
pared with the control group; the before subgroup
(RR = 0.33; 95% CI 0.08, 1.37) showed a non-
significantly lower risk of cGVHD. These results are
shown in Fig. 3.
Relapse
Seven studies reported the number of patients who
had relapsed to the original malignant status after
HSCT in both the MSC and control group. Com-
pared with the control groups, patients in the MSC
group had a lower risk of relapse, but the difference
was not statistically significant (RR = 0.98; 95% CI
0.70, 1.39; I2 = 0%, P = 0.46). According to a subgroup
analysis based on the source of MSC, the U-MSC
subgroup (RR = 0.90; 95% CI 0.581, 1.41) showed a
lower (but not statistically significant) risk of relapse
compared with the control group, whereas the B-
MSC subgroup (RR = 1.20; 95% CI 0.59, 2.41) showed
a higher (but not statistically significant) risk of re-
lapse. According to subgroup analysis based on MSC
infusion time, the after subgroup (RR = 0.86; 95% CI
0.59, 1.24) showed a lower (but not statistically sig-
nificant) risk of relapse compared with the control
group, whereas the before subgroup (RR = 2.44; 95%
CI 0.95, 6.31) showed a higher (but not statistically
significant) risk of relapse. These results are shown in
Fig. 4.
(A)
(B) (C)
Fig. 3 Forest plot of GVHD treatment: whole and subgroup risk estimates of outcome parameters. a Forest plot showing the overall risk estimate
of engraftment and the effects of MSC source and infusion timing. b Forest plot showing the overall risk estimate of acute graft-versus-host
disease (aGVHD) and the effects of MSC source and infusion timing. c Forest plot showing the overall risk estimate of chronic graft-versus-host
disease (cGVHD) and the effects of MSC source and infusion timing
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Death
Seven studies reported the number of patients who died
for any reason after HSCT in both the MSC and control
groups. Compared with the control group, patients in
the MSC group had a lower risk of mortality, but the dif-
ference was not statistically significant (RR = 0.84; 95%
CI 0.61, 1.15; I2 = 1%, P = 0.41). According to a subgroup
analysis based on the source of MSC, both the B-MSC
(RR = 0.83; 95% CI 0.43, 1.61) and U-MSC (RR = 0.85;
95% CI 0.55, 1.31) subgroups showed a non-significant
lower risk of mortality compared with the control group.
According to subgroup analysis based on MSC infusion
time, the after subgroup (RR = 0.75; 95% CI 0.54, 1.06)
showed a lower (but not statistically significant) risk of
death compared with the control group, whereas the be-
fore subgroup (RR = 1.40; 95% CI 0.64, 3.08) showed a
higher (but not statistically significant) risk of death.
These results are shown in Fig. 4.
Death due to relapse
Five studies reported the number of patients who died
after relapse in both the MSC and control groups. Com-
pared with the control group, patients in the MSC group
had a higher risk of death due to relapse, but the differ-
ence was not statistically significant (RR = 1.16; 95% CI
0.93, 1.46; I2 = 0%, P = 0.77). According to a subgroup
(A) (B)
(C) (D)
Fig. 4 Forest plot of GVHD treatment: whole and subgroup risk estimates of outcome parameters. a Forest plot showing the overall risk estimate
of relapse and the effects of MSC source and infusion timing. b Forest plot showing the overall risk estimate of death and the effects of MSC
source and infusion timing. c Forest plot showing the overall risk estimate of death due to relapse and the effects of MSC source and infusion
timing. d Forest plot showing the overall risk estimate of death due to infection and the effects of MSC source and infusion timing
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analysis based on the source of MSC, both the B-MSC
(RR = 1.28; 95% CI 0.76, 2.15) and U-MSC subgroups
(RR = 1.19; 95% CI 0.81, 1.77) showed a higher (but not
statistically significant) risk of death due to relapse com-
pared with the control group. A subgroup analysis based
on MSC infusion time also showed that both the before
(RR = 1.57; 95% CI 0.89, 2.80) and after (RR = 1.10; 95% CI
0.86, 1.41) subgroups had a higher (but not statistically
significant) risk of death due to relapse compared with the
control group. These results are shown in Fig. 4.
Death due to infection
Four studies reported the number of patients who died
as a result of infection in both the MSC and control
groups. Compared with the control group, patients in
the MSC group had a lower risk of death due to infec-
tion, but the difference was not statistically significant
(RR = 0.70; 95% CI 0.31, 1.60; I2 = 0%, P = 0.61). Accord-
ing to a subgroup analysis based on the source of MSC,
both the B-MSC (RR = 0.65; 95% CI 0.11, 3.75) and U-
MSC (RR = 0.60; 95% CI 0.19, 1.94) subgroups showed a
lower (but not statistically significant) risk of death due
to infection compared with the control group. Subgroup
analysis based on MSC infusion time also showed that
both the before (RR = 0.25; 95% CI 0.04, 1.72) and after
(RR = 0.88; 95% CI 0.35, 2.20) subgroups had a lower but
not statistically significant risk of death caused by infec-
tion compared with the control group. These results are
shown in Fig. 4.
Discussion
In this study, we identified, evaluated, and summarized
the findings of relevant clinical studies to estimate the
efficacy of MSC infusion as a GVHD treatment (one
RCT and two nRCTs) and for GVHD prevention (seven
RCTs). The findings of our meta-analyses suggest that
MSC infusion can reduce cGVHD incidence, but not
aGVHD incidence, and has a positive effect on patients
who already have aGVHD by increasing the CR rate and
prolonging survival.
An increasing number of researchers are noting differ-
ences in therapeutic outcomes of MSC treatment among
GVHD populations. The use of MSCs for treating
aGVHD has received extensive attention, while their use
in cases of cGVHD has rarely been reported. In the
three trials included in our analysis, only aGVHD was
investigated. One possible explanation for this is that the
responsiveness of patients with aGVHD to MSCs is su-
perior to that of patients with cGVHD [35]. Since the
number of controlled trials investigating MSCs as a
treatment for GVHD is limited, we only included three
trials. Regardless, our review is the first to evaluate MSC
treatment for GVHD in controlled trials and has verified
the results of a previous meta-analysis [2] of uncon-
trolled studies with a single-arm design.
Compared with the treatment of GVHD, controlled
trials applying MSCs for GVHD prevention have been
widely published. To ensure the reliability of our re-
search, we included only RCTs (n = 7) in our analysis.
To assess the safety of MSC infusion for GVHD preven-
tion, we performed analyses on the outcomes of engraft-
ment, relapse, and death. Whether or not MSCs increase
the incidence of tumor recurrence remains a controversial
topic. In fact, MSCs exert bidirectional effects on tumor
regulation. On the one hand, MSCs might promote tumor
growth and progression, as they can secrete angiogenesis-
promoting and suppress immune response-suppressing
substances [24]; on the other hand, MSCs may inhibit tu-
mors by activating tumor suppression signaling pathways
[40]. Despite some studies showing MSCs increased the
risk of tumor relapse [24, 41], our results showed that
MSC infusion had no significant effect on the incidence of
relapse, death, or time to neutrophil engraftment.
Currently, one of the most successful clinical appli-
cations of MSC infusion is involved in HSCT [42].
However, treatment efficacy varies among clinical tri-
als, and several factors might influence this. To iden-
tify factors related to the efficacy of MSC infusion,
we conducted subgroup meta-analyses for GVHD pre-
vention according to MSC source and MSC infusion
timing. MSCs are readily available from a variety of
tissues, including bone marrow, umbilical cord blood,
adipose tissue, and the placenta. The studies included
in this meta-analysis used only B-MSC or U-MSC,
probably because these are the MSC types used most
commonly in the clinic. Just as the incidence of
GVHD can differ according to the use of stem cells
derived from bone marrow versus cord blood units
[43], the incidence of GVHD also differs according to
use of U-MSCs versus B-MSCs. MSC infusion is ad-
vantageous for reducing cGVHD incidence, but this
was seen only in the U-MSC subgroup and not the
B-MSC subgroup in this study. Although MSCs had
no overall significant effect on the time to neutrophil
engraftment, a significant improvement was seen in
the U-MSC subgroup. Regarding relapse, despite no
significant difference between the overall meta-
analysis and subgroup meta-analysis, use of U-MSCs
tended to reduce relapse, whereas use of B-MSCs
tended to increase relapse. These findings suggest that
B-MSCs are not a good candidate cell type for GVHD
prophylaxis in comparison with U-MSCs.
Although adult bone marrow has served as the trad-
itional source of MSCs, fetal-type MSCs, such as U-
MSCs, have also proven to be an excellent alternative
source [44]. These MSCs can be obtained more easily,
proliferate faster in vitro, and show reduced
Zhao et al. Stem Cell Research & Therapy          (2019) 10:182 Page 10 of 13
immunogenicity [45–47]. More importantly, compared
with adult-type MSCs, fetal-type MSCs have stronger
immunosuppressive effects [48]. The reduced immuno-
genicity and stronger immunosuppressive effects of U-
MSCs make them ideal candidates for cell-based therap-
ies, especially for diseases associated with an immune re-
sponse [48]. The use of U-MSCs for reducing cGVHD
incidence and promoting engraftment shows much
promise, and further clinical studies involving fetal-type
MSCs, such as U-MSCs, in HSCT are urgently needed.
Infusion timing, of which little is known, is another
important factor when evaluating the efficacy of
MSC-based therapy [49, 50]. Our subgroup analysis of
infusion timing revealed that MSC infusion after
HSCT had a greater beneficial effect, with significant
improvements seen in engraftment and a lower risk
of cGVHD incidence occurring only in the after, and
not the before, subgroup. In addition, despite a lack
of statistical significance, MSC infusion after HSCT
tended to reduce the incidence rates of relapse and
death, whereas MSC infusion before HSCT tended to
increase the incidence rates. The influence of timing
of MSC infusion might be related to differences in
the immune and inflammation microenvironment in
vivo over time [51].
CGVHD is the leading cause of mortality and mor-
bidity after HSCT. Given that our findings showed
that MSC infusion decreased cGVHD incidence, its
inability to prolong survival seems to be inexplicable
and warrants further study. In addition to cGVHD,
relapse and infection are the other major causes of
death after HSCT [52]. We therefore conducted ana-
lyses to determine how MSC infusion affected death
due to relapse and death. The results showed that MSC
infusion may increase the likelihood of death due to relapse
after HSCT. Although the increase was not statistically sig-
nificant, it remains a concern. Along with the findings
showing that the use of B-MSC infusion, and MSC infusion
before HSCT, also tended to increase the risk of relapse,
MSCs for GVHD prevention failed to enhance survival,
which may be related to a higher incidence of relapse and
death due to relapse.
There were several limitations to this systematic review.
First, we could not precisely estimate the overall treatment
efficacy because of the small number of studies and their
small sample sizes, especially with respect to GVHD treat-
ment. Although we included both RCTs and nRCTs on
GVHD treatment, there were insufficient studies and pa-
tients to perform a subgroup meta-analysis. Our findings
could be further validated or refined by integrating other
data, provided additional relevant literature is published
soon. In addition, we were unable to assess publication bias,
either statistically or visually, because of the limited number
of included studies. Second, possibly because of the small
number of studies and their small sample sizes, the statis-
tical power was limited. The possible advantages of U-
MSCs over B-MSCs, and of MSC infusion after HSCT ver-
sus before HSCT, in terms of decreasing relapse or death,
were not statistically demonstrated. Therefore, these results
require further validation via additional research. The pos-
sible disadvantages of B-MSCs and MSC infusion before
HSCT also need to be verified to avoid harming patients. In
addition, the possibility that MSC infusion may increase the
likelihood of death due to relapse also needs to be further
explored. Third, we were unable to assess the effects of
some important parameters such as the recipient age, type
of MSC donor, type of cancer being treated, preparative
therapy before transplantation, and role of HLA mismatch-
ing which all could influence the clinical outcomes. In our
initial study design, subgroup analyses were to be per-
formed if all seven studies reported the information re-
quired and the data could be stratified. Unfortunately
however, subgroup analyses based on these variables
could not be performed because of an inadequate
number of studies or relevant data. These limitations
introduced unreliability into our study, but our work
should still be interesting to researchers and clinicians
devoted to use of MSCs as a safe and effective ap-
proach for GVHD.
Conclusion
In conclusion, the evidence from RCTs and nRCTs
suggests that MSCs can play a useful role in HSCT,
including by promoting engraftment (U-MSC), pre-
venting GVHD (mainly cGVHD), and ameliorating
GVHD (aGVHD). MSC infusion enhanced survival
only in the context of treating, and not preventing
GVHD. For GVHD prevention, use of U-MSCs and
infusion after HSCT were optimal for suppressing
cGVHD incidence and promoting engraftment and
may decrease the incidence rates of relapse and
death. The use of B-MSCs and infusion before
HSCT may be harmful to the patient and thus re-
quires serious consideration. In closing, these find-
ings need further confirmation as the limitations
imposed on this meta-analysis by the small number
of included studies and their small number of pa-
tients. Therefore, future studies need to determine
the clinical impact of MSC infusion for treating
GVHD, and our research needs to be validated via a
sufficient number of high-quality clinical trials with
large numbers of patients.
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